Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Conditions
C3 Glomerulopathy · Immune-complex-membranoproliferative Glomerulonephritis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Childrens Hospital Colorado, Aurora, Colorado, United States
Contact: Principal Investigator (Bradley Dixon)Georgia Nephrology Research Inst, Lawrenceville, Georgia, United States
Contact: Principal Investigator (James A Tumlin)University of Iowa Health Care, Iowa City, Iowa, United States
Contact: Principal Investigator (Carla Nester)University of Minnesota, Minneapolis, Minnesota, United States
Contact: Principal Investigator (Nattawat Klomjit)Col Uni Med Center New York Presby, New York, New York, United States
Contact: Principal Investigator (Andrew S Bomback)Novartis Investigative Site, CABA, Buenos Aires, Argentina
Novartis Investigative Site, Buenos Aires, Argentina
Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site, Recife, Pernambuco, Brazil
Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site, Botucatu, São Paulo, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, Salvador, Brazil
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Prague, Czechia
Novartis Investigative Site, Montpellier, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Toulouse, France
Novartis Investigative Site, Erlangen, Germany
Novartis Investigative Site, Essen, Germany
Novartis Investigative Site, Hamburg, Germany
Novartis Investigative Site, Heidelberg, Germany
Novartis Investigative Site, Mainz, Germany
Novartis Investigative Site, Heraklion Crete., Greece
Novartis Investigative Site, Thessaloniki, Greece
Novartis Investigative Site, Petah Tikva, Israel
Novartis Investigative Site, Petah Tikva, Israel
Novartis Investigative Site, Bari, BA, Italy
Novartis Investigative Site, Ranica, BG, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Nagoya, Aichi-ken, Japan
Novartis Investigative Site, Asahikawa, Hokkaido, Japan
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Takatsuki, Osaka, Japan
Novartis Investigative Site, Ohtsu, Shiga, Japan
Novartis Investigative Site, Hachiōji, Tokyo, Japan
Novartis Investigative Site, Niigata, Japan
Novartis Investigative Site, Leiden, South Holland, Netherlands
Novartis Investigative Site, Pamplona, Navarre, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Seville, Spain
Novartis Investigative Site, Bern, Switzerland
Novartis Investigative Site, Köseköy, Kocaeli, Turkey (Türkiye)
Novartis Investigative Site, Kayseri, Melikgazi, Turkey (Türkiye)
Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)
Novartis Investigative Site, Newcastle upon Tyne, Tyne and Wear, United Kingdom
Novartis Investigative Site, Cardiff, United Kingdom
Novartis Investigative Site, London, United Kingdom
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals